Keros Therapeutics Inc (KROS) financials
Keros Therapeutics revenue and earnings by year
Keros Therapeutics's revenue was $244 million in the fiscal year to December 31, 2025, up 6775.0% from the year before. Net income was $87.0 million, 35.7% of revenue. Since the fiscal year to December 31, 2018, revenue has grown 57.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2021 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|
| Revenue | 244 | 4 | 0 | 20 | 10 | 10 |
| Revenue growth | 6775.0% | 2251.0% | -99.2% | 101.0% | 0.0% | — |
| Operating income | 68 | -211 | -170 | -56 | -11 | -2 |
| Operating margin | 27.7% | -5939.0% | -112543.7% | -280.5% | -105.6% | -16.9% |
| Net income | 87 | -187 | -153 | -59 | -14 | -2 |
| Net margin | 35.7% | -5277.5% | -101319.2% | -292.3% | -141.4% | -23.5% |
| Diluted EPS | $2.30 | -$5.00 | -$5.20 | -$2.52 | -$6.08 | — |
| Free cash flow | 106 | -163 | -127 | -63 | -16 | 7 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open KROS in Markets.
See also: KROS returns
No forecast, no recommendation. This page describes Keros Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.